News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
25,991 Results
Type
Article (3897)
Company Profile (4)
Press Release (22088)
Multimedia
Podcasts (29)
Webinars (4)
Section
Business (8818)
Career Advice (39)
Deals (1249)
Drug Delivery (20)
Drug Development (4423)
Employer Resources (12)
FDA (726)
Job Trends (1078)
News (14923)
Policy (1561)
Tag
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (2)
Alliances (2273)
ALS (2)
Alzheimer's disease (38)
Antibody-drug conjugate (ADC) (84)
Approvals (734)
Artificial intelligence (24)
Autoimmune disease (13)
Automation (2)
Bankruptcy (9)
Best Places to Work (846)
BIOSECURE Act (7)
Biosimilars (9)
Biotechnology (1)
Bladder cancer (21)
Brain cancer (11)
Breast cancer (70)
Cancer (519)
Cardiovascular disease (42)
Career advice (42)
Career pathing (2)
CAR-T (12)
CDC (14)
Cell therapy (23)
Cervical cancer (6)
Clinical research (3784)
Collaboration (87)
Company closure (3)
Compensation (7)
Complete response letters (7)
COVID-19 (206)
CRISPR (2)
C-suite (93)
Cystic fibrosis (2)
Data (252)
Depression (4)
Dermatology (1)
Diabetes (7)
Diagnostics (95)
Diversity, equity & inclusion (3)
Drug discovery (14)
Drug pricing (49)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (2310)
Editorial (8)
Employer branding (6)
Employer resources (12)
Events (2509)
Executive appointments (95)
FDA (829)
Funding (52)
Gene editing (8)
Generative AI (4)
Gene therapy (17)
GLP-1 (83)
Government (332)
Grass and pollen (1)
Guidances (8)
Healthcare (483)
HIV (13)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (33)
Immuno-oncology (16)
Indications (9)
Infectious disease (236)
Inflammatory bowel disease (9)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (373)
IRA (12)
Job creations (284)
Job search strategy (38)
JPM (9)
Kidney cancer (6)
Labor market (11)
Layoffs (65)
Leadership (2)
Legal (402)
Liver cancer (8)
Longevity (1)
Lung cancer (117)
Lymphoma (14)
Machine learning (2)
Management (4)
Manufacturing (51)
MASH (7)
Medical device (83)
Medtech (83)
Mergers & acquisitions (921)
Metabolic disorders (52)
mRNA (35)
Multiple sclerosis (14)
Neurodegenerative disease (15)
Neuropsychiatric disorders (9)
Neuroscience (84)
NextGen: Class of 2026 (199)
Non-profit (91)
Now hiring (2)
Obesity (36)
Opinion (37)
Ovarian cancer (24)
Pain (6)
Pancreatic cancer (7)
Parkinson's disease (5)
Patents (22)
Patient recruitment (10)
People (3974)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1084)
Phase 2 (1697)
Phase 3 (1585)
Pipeline (277)
Policy (61)
Postmarket research (201)
Preclinical (278)
Press Release (2)
Prostate cancer (6)
Psychedelics (9)
Radiopharmaceuticals (17)
Rare diseases (34)
Real estate (213)
Recruiting (4)
Regulatory (1094)
Reports (7)
Research institute (72)
Resumes & cover letters (1)
RNA editing (1)
RSV (17)
Schizophrenia (4)
Series A (14)
Series B (9)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (214)
Stomach cancer (9)
Supply chain (7)
Tariffs (23)
The Weekly (27)
Vaccines (156)
Venture capital (14)
Weight loss (31)
Women's health (4)
Worklife (1)
Date
Last 7 days (18)
Last 30 days (97)
Last 365 days (1004)
2026 (368)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2976)
2021 (2787)
2020 (2293)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1327)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (2)
Asia (1596)
Australia (404)
California (243)
Canada (96)
China (112)
Colorado (5)
Connecticut (7)
Delaware (14)
Europe (4395)
Florida (69)
Georgia (2)
Illinois (11)
India (1)
Indiana (2)
Japan (62)
Kansas (1)
Kentucky (1)
Maryland (57)
Massachusetts (270)
Michigan (1)
Minnesota (3)
Mississippi (1)
Missouri (3)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (308)
New York (90)
North Carolina (24)
Northern California (126)
Ohio (3)
Oregon (1)
Pennsylvania (27)
Rhode Island (4)
South America (61)
Southern California (89)
Tennessee (1)
Texas (29)
United States (1179)
Utah (8)
Virginia (8)
Washington D.C. (5)
Washington State (30)
West Virginia (1)
Wisconsin (2)
25,991 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026
·
7 min read
People
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo
The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent months, including GSK’s Emma Walmsley and Novo Nordisk’s Lars Fruergaard Jørgensen.
February 12, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
aptaTargets transferred ApTOLL to Merck KGaA, Darmstadt, Germany
ApTOLL completed a Phase 1b/2 clinical trial for acute ischemic stroke with positive results. Merck KGaA, Darmstadt, Germany, to assume clinical development and commercialization of ApTOLL.
May 22, 2025
·
1 min read
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
·
3 min read
·
Tristan Manalac
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Kidney cancer
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
April 21, 2026
·
2 min read
·
Tristan Manalac
Deals
Roche sticks with C4T, adding up to $1B for molecular glue partnership
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
April 9, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
·
5 min read
·
Nick Paul Taylor
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
1 of 2,600
Next
